Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2000

View Archived Issues

Inhibition of NK cells by cancer cells from patients with CML prevented by Maxamine

SangStat's Thymoglobulin granted orphan drug designation in U.S.

The hypothalamo-hypophyseal-adrenal axis influences arthritis development, treatment

Lisinopril found to regress myocardial fibrosis in hypertensive patients

Consensus on Statins -- International Task Force Webcast now available on demand

Vernalis's clinical development programs continue to make good progress

ImmunoGen/SmithKline Beecham open second trial of cancer treatment

Antidepressants with novel mechanism of action identified at SB

AstraZeneca presents new DOP-selective analgesic candidate in Bologna

MBR ligands under development at Dainippon as safe and effective anxiolytic agents

SRI reports synthesis and activity of new anti-MAC compounds targeting DHFR

Novel anti-MRSA cephalosporin and prodrug emerge from Microcide/R.W. Johnson collaboration

Coulter acquires rights to anticancer compounds

Broad-spectrum antiherpesvirus agents from Pharmacia target viral polymerase

Zefix approved in Japan for chronic HBV infection

Japanese approval granted for Diovan, a new antihypertensive agent

Merck discusses preparation and methods of using integrin antagonists for bone disorders, etc.

Synthesis and use of quinazoline-based VEGF receptor tyrosine kinase inhibitors

Research program at SB on orexin receptor antagonists yields results

Roche discloses novel MMP inhibitors particularly useful in the control of cancer

Lactam factor Xa inhibitors designed by BMS research groups

Protein farnesyltransferase inhibitors and their use in cancer treatment described by Pfizer

Merck patents new series of tachykinin NK1 receptor antagonists

Aptosyn NDA for FAP indication not approvable at this time

FDA denies approval of Foscan

Promising antischizophrenia agent shows safety and efficacy in phase III

Vical reports interim data from phase II trial of Leuvectin

Corixa and Purdue establish agreement for therapeutic antibodies for cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.